Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C.

J Clin Oncol. 2018 May 7:JCO2018782292. doi: 10.1200/JCO.2018.78.2292. [Epub ahead of print]

PMID:
29733771
2.

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.

Guerin M, Rezai K, Isambert N, Campone M, Autret A, Pakradouni J, Provansal M, Camerlo J, Sabatier R, Bertucci F, Charafe-Jauffret E, Hervieu A, Extra JM, Viens P, Lokiec F, Boher JM, Gonçalves A.

Eur J Cancer. 2017 Nov;86:28-36. doi: 10.1016/j.ejca.2017.08.025. Epub 2017 Sep 23.

PMID:
28950146
3.

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.

Vázquez R, Riveiro ME, Astorgues-Xerri L, Odore E, Rezai K, Erba E, Panini N, Rinaldi A, Kwee I, Beltrame L, Bekradda M, Cvitkovic E, Bertoni F, Frapolli R, D'Incalci M.

Oncotarget. 2017 Jan 31;8(5):7598-7613. doi: 10.18632/oncotarget.13814.

4.

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.

Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, Odore E, Rezai K, Bekradda M, Inghirami G, D'Incalci M, Noel K, Cvitkovic E, Raymond E, Bertoni F.

Oncotarget. 2016 Dec 20;7(51):84675-84687. doi: 10.18632/oncotarget.13181.

5.

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.

Gaudio E, Tarantelli C, Ponzoni M, Odore E, Rezai K, Bernasconi E, Cascione L, Rinaldi A, Stathis A, Riveiro E, Cvitkovic E, Zucca E, Bertoni F.

Oncotarget. 2016 Sep 6;7(36):58142-58147. doi: 10.18632/oncotarget.10983.

6.

OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.

Berenguer-Daizé C, Astorgues-Xerri L, Odore E, Cayol M, Cvitkovic E, Noel K, Bekradda M, MacKenzie S, Rezai K, Lokiec F, Riveiro ME, Ouafik L.

Int J Cancer. 2016 Nov 1;139(9):2047-55. doi: 10.1002/ijc.30256. Epub 2016 Jul 30.

7.

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.

Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, Herait P, Kahatt C, Lokiec F, Salles G, Facon T, Palumbo A, Cunningham D, Zucca E, Thieblemont C.

Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18.

PMID:
27063978
8.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H.

Lancet Haematol. 2016 Apr;3(4):e186-95. doi: 10.1016/S2352-3026(15)00247-1. Epub 2016 Mar 18.

PMID:
27063977
9.

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.

Bernadou G, Campone M, Merlin JL, Gouilleux-Gruart V, Bachelot T, Lokiec F, Rezai K, Arnedos M, Diéras V, Jimenez M, Paintaud G, Ternant D.

Br J Clin Pharmacol. 2016 May;81(5):941-8. doi: 10.1111/bcp.12875. Epub 2016 Mar 7.

10.

Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer.

Alberini JL, Boisgard R, Guillermet S, Siquier K, Jego B, Thézé B, Urien S, Rezaï K, Menet E, Maroy R, Dollé F, Kühnast B, Tavitian B.

Mol Imaging Biol. 2016 Aug;18(4):617-26. doi: 10.1007/s11307-015-0916-7.

11.

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.

Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, Kahatt C, Raffoux E, Stathis A, Thieblemont C, Quesnel B, Cunningham D, Riveiro ME, Rezaï K.

Clin Pharmacokinet. 2016 Mar;55(3):397-405. doi: 10.1007/s40262-015-0327-6.

PMID:
26341814
12.

A single-dose PK study of onapristone including the effect of food on absorption.

Rezai K, Chassard D, Denot C, Proniuk S, Zukiwski A, Gilles E, Ramos HL, Patat A, Bexon A, Lokiec F.

Cancer Chemother Pharmacol. 2015 Jul;76(1):171-7. doi: 10.1007/s00280-015-2754-3. Epub 2015 May 26.

PMID:
26006702
13.

Are IPL home devices really foolproof?

Schmitt L, Rezai K, Karsai S.

J Eur Acad Dermatol Venereol. 2016 May;30(5):856-7. doi: 10.1111/jdv.13025. Epub 2015 Feb 24. No abstract available.

PMID:
25712139
14.

A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).

Fumoleau P, Koch KM, Brain E, Lokiec F, Rezai K, Awada A, Hayward L, Werutsky G, Bogaerts J, Marréaud S, Cardoso F.

Breast. 2014 Oct;23(5):663-9. doi: 10.1016/j.breast.2014.07.003. Epub 2014 Jul 24.

PMID:
25065668
15.

Extracellular adenosine triphosphate affects the response of human macrophages infected with Mycobacterium tuberculosis.

Dubois-Colas N, Petit-Jentreau L, Barreiro LB, Durand S, Soubigou G, Lecointe C, Klibi J, Rezaï K, Lokiec F, Coppée JY, Gicquel B, Tailleux L.

J Infect Dis. 2014 Sep 1;210(5):824-33. doi: 10.1093/infdis/jiu135. Epub 2014 Mar 5.

PMID:
24604822
16.

Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients.

Lévy P, Gligorov J, Antoine M, Rezai K, Lévy E, Selle F, Saintigny P, Lokiec F, Avenin D, Beerblock K, Lotz JP, Bernaudin JF, Fajac A.

Breast Cancer Res Treat. 2013 Jun;139(2):421-8. doi: 10.1007/s10549-013-2545-7. Epub 2013 May 11.

PMID:
23666532
17.

Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezaï K, Buchbinder A.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1499-506. doi: 10.1007/s00280-013-2149-2. Epub 2013 Mar 30.

18.

Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.

Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M.

Cancer. 2012 Dec 15;118(24):6144-51. doi: 10.1002/cncr.27647. Epub 2012 Jun 6.

19.

Continuation of high-dose vancomycin despite nephrotoxicity.

Teng CB, Rezai K, Itokazu GS, Xamplas RC, Glowacki RC, Rodvold KA, Weinstein RA, Schwartz DN.

Antimicrob Agents Chemother. 2012 Jun;56(6):3470-1; author reply 3472. doi: 10.1128/AAC.00240-12. No abstract available.

20.

[Adaptation of methotrexate determination in serum with Unicel DxC600(®)].

Saada S, Olichet B, Bronzini T, Berrafato S, Lokiec F, Rezaï K, Troalen F, Sastre X.

Ann Biol Clin (Paris). 2012 May-Jun;70(3):277-86. doi: 10.1684/abc.2012.0708. French.

21.

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.

Brain E, Isambert N, Dalenc F, Diéras V, Bonneterre J, Rezai K, Jimenez M, Mefti-Lacheraf F, Cottura E, Tresca P, Vanlemmens L, Mahier-Aït Oukhatar C, Lokiec F, Fumoleau P.

Br J Cancer. 2012 Feb 14;106(4):673-7. doi: 10.1038/bjc.2011.591. Epub 2012 Jan 12.

22.

Severe docetaxel overdose induced by pharmacokinetic interaction with dronedarone.

Vodovar D, Mongardon N, Moachon L, Arnaout M, Beuzeboc P, Lokiec F, Rezai K, Pène F.

J Clin Oncol. 2011 Aug 20;29(24):e694-5. doi: 10.1200/JCO.2011.35.8002. Epub 2011 Jul 5. No abstract available.

PMID:
21730272
23.

Surgical management of endocarditis: the society of thoracic surgeons clinical practice guideline.

Byrne JG, Rezai K, Sanchez JA, Bernstein RA, Okum E, Leacche M, Balaguer JM, Prabhakaran S, Bridges CR, Higgins RS.

Ann Thorac Surg. 2011 Jun;91(6):2012-9. doi: 10.1016/j.athoracsur.2011.01.106. No abstract available.

PMID:
21620012
24.

Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.

Rezai K, Urien S, Isambert N, Roche H, Dieras V, Berille J, Bonneterre J, Brain E, Lokiec F.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1529-36. doi: 10.1007/s00280-011-1650-8. Epub 2011 Apr 26.

PMID:
21519841
25.

Impaired glucose tolerance and metabolic syndrome in idiopathic polyneuropathy: the role of pain and depression.

Rezania K, Soliven B, Rezai KA, Roos RP.

Med Hypotheses. 2011 Apr;76(4):538-42. doi: 10.1016/j.mehy.2010.12.012. Epub 2011 Jan 20.

PMID:
21255940
26.

A phase I trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma.

Tao Y, Rezaï K, Brain E, Etessami A, Lusinchi A, Temam S, Urien S, Van ML, Vauzelle-Kervroedan F, Lokiec F, Daly-Schveitzer N, Bourhis J.

Radiother Oncol. 2011 Jan;98(1):42-7. doi: 10.1016/j.radonc.2010.11.008. Epub 2010 Dec 20.

PMID:
21176985
27.

Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.

Fajac A, Gligorov J, Rezai K, Lévy P, Lévy E, Selle F, Beerblock K, Avenin D, Saintigny P, Hugonin S, Bernaudin JF, Lokiec F.

Br J Cancer. 2010 Aug 10;103(4):560-6. doi: 10.1038/sj.bjc.6605789. Epub 2010 Jul 13.

28.

Platination of telomeric DNA by cisplatin disrupts recognition by TRF2 and TRF1.

Ourliac-Garnier I, Poulet A, Charif R, Amiard S, Magdinier F, Rezaï K, Gilson E, Giraud-Panis MJ, Bombard S.

J Biol Inorg Chem. 2010 Jun;15(5):641-54. doi: 10.1007/s00775-010-0631-4. Epub 2010 Feb 27.

PMID:
20191372
29.

Suction curettage of the sweat glands--an update.

Rezai K.

Dermatol Surg. 2009 Jul;35(7):1126-9. doi: 10.1111/j.1524-4725.2009.01198.x. Epub 2009 Apr 28. No abstract available.

PMID:
19438684
30.

Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort.

Adeyemi O, Rezai K, Bahk M, Badri S, Thomas-Gossain N.

AIDS Patient Care STDS. 2008 Dec;22(12):941-5. doi: 10.1089/apc.2008.0119.

PMID:
19072100
31.

Coronary artery calcification on electron beam computed tomography: a 6-year follow-up study of HIV-infected patients.

Adeyemi OM, Rezai K, Akimov S, Hwang J, Sha BE, Kessler HA.

J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):113-4. doi: 10.1097/QAI.0b013e31816de252. No abstract available.

PMID:
18725810
32.

AcrySof Natural filter decreases blue light-induced apoptosis in human retinal pigment epithelium.

Rezai KA, Gasyna E, Seagle BL, Norris JR Jr, Rezaei KA.

Graefes Arch Clin Exp Ophthalmol. 2008 May;246(5):671-6. doi: 10.1007/s00417-006-0484-2. Epub 2008 Feb 26.

PMID:
18299878
33.

Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study.

Brain EG, Rezai K, Lokiec F, Gutierrez M, Urien S.

Br J Clin Pharmacol. 2008 Apr;65(4):607-10. doi: 10.1111/j.1365-2125.2007.03095.x. Epub 2008 Feb 21.

34.

Septic pulmonary emboli and bacteremia associated with deep tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.

Lin MY, Rezai K, Schwartz DN.

J Clin Microbiol. 2008 Apr;46(4):1553-5. doi: 10.1128/JCM.02379-07. Epub 2008 Jan 30.

35.

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.

Rezaï K, Lokiec F, Grandjean I, Weill S, de Cremoux P, Bordier V, Ekue R, Garcia M, Poupon MF, Decaudin D.

BMC Pharmacol. 2007 Oct 27;7:13.

36.

Latanoprost induced iritis after vitrectomy surgery.

Bhatia S, Rezai KA.

Retin Cases Brief Rep. 2007 Winter;1(1):40. doi: 10.1097/01.ICB.0000256946.49953.35. No abstract available.

PMID:
25390234
37.

Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.

Brain EG, Rezai K, Weill S, Gauzan MF, Santoni J, Besse B, Goupil A, Turpin F, Urien S, Lokiec F.

Cancer Chemother Pharmacol. 2007 Aug;60(3):375-81. Epub 2006 Nov 15.

PMID:
17106751
38.

Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.

Paci A, Rezai K, Deroussent A, De Valeriola D, Re M, Weill S, Cvitkovic E, Kahatt C, Shah A, Waters S, Weems G, Vassal G, Lokiec F.

Drug Metab Dispos. 2006 Nov;34(11):1918-26. Epub 2006 Aug 8.

39.

Variations of soluble fas and cytokeratin 18-Asp 396 neo-epitope in different cancers during chemotherapy.

Pichon MF, Labroquère M, Rezaï K, Lokiec F.

Anticancer Res. 2006 May-Jun;26(3B):2387-92.

40.

Learning by doing: developing fellows' academic skills through collaborative research.

Madariaga MG, Evans AT, Brobbey W, Phillips M, Lo E, Rezai K, Schwartz DN, Trenholme GM, Weinstein RA.

Med Teach. 2006 Feb;28(1):77-80.

PMID:
16627329
41.

Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer.

Sharma S, Rezai K, Driscoll D, Odunsi K, Lele S.

Gynecol Oncol. 2006 Oct;103(1):181-5. Epub 2006 Mar 30.

PMID:
16574203
42.

Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.

Urien S, Rezaí K, Lokiec F.

J Pharmacokinet Pharmacodyn. 2005 Dec;32(5-6):817-33.

PMID:
16284918
43.

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus.

Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA.

J Clin Microbiol. 2005 Oct;43(10):5285-7.

44.

Time-resolved detection of melanin free radicals quenching reactive oxygen species.

Seagle BL, Rezai KA, Gasyna EM, Kobori Y, Rezaei KA, Norris JR Jr.

J Am Chem Soc. 2005 Aug 17;127(32):11220-1.

PMID:
16089432
45.

Melanin photoprotection in the human retinal pigment epithelium and its correlation with light-induced cell apoptosis.

Seagle BL, Rezai KA, Kobori Y, Gasyna EM, Rezaei KA, Norris JR Jr.

Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):8978-83. Epub 2005 Jun 10.

46.

Disseminated Fusarium infection presenting as bilateral endogenous endophthalmitis in a patient with acute myeloid leukemia.

Rezai KA, Eliott D, Plous O, Vazquez JA, Abrams GW.

Arch Ophthalmol. 2005 May;123(5):702-3. No abstract available.

PMID:
15883296
47.

Near confluent laser photocoagulation for the treatment of threshold retinopathy of prematurity.

Rezai KA, Eliott D, Ferrone PJ, Kim RW.

Arch Ophthalmol. 2005 May;123(5):621-6.

PMID:
15883280
48.

Derivation and comparative assessment of retinal pigment epithelium from human embryonic stem cells using transcriptomics.

Klimanskaya I, Hipp J, Rezai KA, West M, Atala A, Lanza R.

Cloning Stem Cells. 2004;6(3):217-45.

PMID:
15671670
49.

Kikuchi-Fujimoto disease: hydroxychloroquine as a treatment.

Rezai K, Kuchipudi S, Chundi V, Ariga R, Loew J, Sha BE.

Clin Infect Dis. 2004 Dec 15;39(12):e124-6. Epub 2004 Nov 21.

PMID:
15578393
50.

Optical coherence tomographic findings in pregnancy-associated central serous chorioretinopathy.

Rezai KA, Eliott D.

Graefes Arch Clin Exp Ophthalmol. 2004 Dec;242(12):1014-6. Epub 2004 Oct 13.

PMID:
15490217

Supplemental Content

Support Center